NEW YORK (GenomeWeb) – Clinical genomic testing company Variantyx has received a $7 million investment from Israeli firm Pitango Venture Capital.
Pitango, based in Herzliya, said today that the funding round is part of its new Pitango HealthTech Fund, which the firm aims to close at $150 million.
Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.
Two years ago, the company said it was integrating its testing pipeline with FDNA's Face2Gene phenotyping technology. Earlier this year, Variantyx launched a program to enroll rare-disease patients for free whole genome sequencing-based testing.